Damiën van Berlo , Vivian V.T. Nguyen , Vasiliki Gkouzioti , Kirsten Leineweber , Marianne C. Verhaar , Bas W.M. van Balkom
{"title":"Stem cells, organoids, and organ-on-a-chip models for personalized in vitro drug testing","authors":"Damiën van Berlo , Vivian V.T. Nguyen , Vasiliki Gkouzioti , Kirsten Leineweber , Marianne C. Verhaar , Bas W.M. van Balkom","doi":"10.1016/j.cotox.2021.08.006","DOIUrl":null,"url":null,"abstract":"<div><p>Breakthroughs in stem cell biology and microfluidics technology have opened doors to <em>in vitro</em> screening platforms for personalized testing of safety (pharmaceuticals, nutrients, chemicals) and efficacy (pharmaceuticals, nutraceuticals). Major breakthrough technologies include development of induced pluripotent stem cells, the development of induced pluripotent stem cell-derived organoids and adult stem cell-derived organoids, and the generation of organ-on-a-chip and multi-organ-on-a-chip models to mimic human physiology <em>in vitro</em>. These technologies are highly complementary and offer tremendous potential for improved efficiency in drug development and chemical safety testing. In the current review, we will provide an overview of recent advances in <em>in vitro</em> modeling for personalized drug testing based on stem cell and organ-on-a-chip technologies and illustrate how these developments will eventually lead to the replacement of animal testing. Particular focus will be on multi-organ-on-chip human disease models, which have the potential to be the gold standard of the future for the investigation of safety, toxicity, and efficacy of newly developed medicines.</p></div>","PeriodicalId":37736,"journal":{"name":"Current Opinion in Toxicology","volume":"28 ","pages":"Pages 7-14"},"PeriodicalIF":6.1000,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.cotox.2021.08.006","citationCount":"13","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Toxicology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2468202021000413","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"TOXICOLOGY","Score":null,"Total":0}
引用次数: 13
Abstract
Breakthroughs in stem cell biology and microfluidics technology have opened doors to in vitro screening platforms for personalized testing of safety (pharmaceuticals, nutrients, chemicals) and efficacy (pharmaceuticals, nutraceuticals). Major breakthrough technologies include development of induced pluripotent stem cells, the development of induced pluripotent stem cell-derived organoids and adult stem cell-derived organoids, and the generation of organ-on-a-chip and multi-organ-on-a-chip models to mimic human physiology in vitro. These technologies are highly complementary and offer tremendous potential for improved efficiency in drug development and chemical safety testing. In the current review, we will provide an overview of recent advances in in vitro modeling for personalized drug testing based on stem cell and organ-on-a-chip technologies and illustrate how these developments will eventually lead to the replacement of animal testing. Particular focus will be on multi-organ-on-chip human disease models, which have the potential to be the gold standard of the future for the investigation of safety, toxicity, and efficacy of newly developed medicines.
期刊介绍:
The aims and scope of Current Opinion in Toxicology is to systematically provide the reader with timely and provocative views and opinions of the highest qualified and recognized experts on current advances in selected topics within the field of toxicology. The goal is that Current Opinion in Toxicology will be an invaluable source of information and perspective for researchers, teachers, managers and administrators, policy makers and students. Division of the subject into sections: For this purpose, the scope of Toxicology is divided into six selected high impact themed sections, each of which is reviewed once a year: Mechanistic Toxicology, Metabolic Toxicology, Risk assessment in Toxicology, Genomic Toxicology, Systems Toxicology, Translational Toxicology.